Analysts have raised their price target for Medacta Group from CHF156.91 to CHF164.46, citing modest adjustments to growth and margin expectations as reflected in updated forecasts.
What's in the News
- Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth in the range of 16% to 18% in constant currency, subject to unforeseen events (Key Developments).
- The company's earnings guidance for 2025 was recently raised. The revenue growth forecast increased from a previous range of 13% to 15% to the updated 16% to 18%, reflecting strong performance across multiple geographies (Key Developments).
- Medacta Group upgraded its midterm outlook and now expects constant currency revenue growth in the range of 10% to 14% (Key Developments).
Valuation Changes
- The Fair Value Estimate has increased from CHF156.91 to CHF164.46.
- The Discount Rate has decreased slightly from 4.62% to 4.60%.
- The Revenue Growth Expectation has declined from 13.62% to 12.37%.
- The Net Profit Margin Forecast has decreased marginally from 13.55% to 13.38%.
- The Future P/E Ratio has risen from 31.0x to 33.1x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.